Navigation Links
Radiopharmaceutical Cardiolite has 15 Percent More Market Share than Myoview for September 2008
Date:11/11/2008

Administration of Astellas's Lexiscan in Patients Increased by 58 Percent From August to September 2008, According To New Data from Arlington Medical Resources

MALVERN, Pa., Nov. 11 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Lantheus Medical Imaging's Cardiolite has 15 percent more market share than General Electric's Myoview for September 2008. Both Cardiolite and Myoview are administered intravenously as part of the Myocardial Perfusion Imaging Stress Test to highlight areas of the heart. The Myocardial Perfusion Imaging Stress Test is given to help diagnose coronary artery disease.

"Compared to data from our September 2007 audit, Cardiolite use has dropped nine percent. Even so, Cardiolite continues to dominate the radiopharmaceutical market," stated Anna Fisher, analyst at AMR.

The newly released edition of the Myocardial Perfusion Study Monthly Monitor also finds the number of patients who were administered Astellas's Lexiscan (regadenoson) increased 58.5 percent from August 2008 to September 2008. Lexiscan is the newest pharmacologic stress agent on the market--introduced in June 2008--and it is used in patients unable to undergo exercise stress testing.

Why Pharmaceutical and Medical Device Companies Need this Information

The Myocardial Perfusion Study Monthly Monitor enables pharmaceutical and medical device companies to track the number of nuclear myocardial perfusion tests performed in hospital and non-hospital settings. For each study month, this audit provides projections of myocardial perfusion studies performed with each of the various radiopharmaceutical products. Projections are also provided for the number of studies involving pharmacologic stressing with intravenous adenosine, intravenous dipyridamole, intravenous regadenoson and intravenous dobutamine.

About the Myocardial Perfusion Study Monthly Monitor AMR's Myocardial Perfusion Study Monthly Monitor is a syndicated audit designed to track the number of nuclear myocardial perfusion tests performed in hospital and non-hospital settings. The audit is available once a month.

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
2. For the First Time this Winter Consumers Have an Electronic Green Solution that Eliminates 99.97 Percent of Indoor Air Pollution
3. Volcano Reports 40 Percent Growth in Quarterly Revenues
4. Healthy bones program reduces hip fractures by 37 percent
5. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
6. Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008
7. Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
8. HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth
9. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
10. Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets
11. Death rate 70 percent lower at top-rated hospitals: HealthGrades annual hospital quality study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot on ... CIOReview. , In a deliberate session with the honorary industrial experts, a list of ... with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample Management ...
(Date:5/25/2016)... ... 25, 2016 , ... DKT International, one of the largest ... pleased to release their 2015 global impact data. In 2015, DKT served over ... deaths and 3.8 million unsafe abortions across 21 countries worldwide. , “We ...
(Date:5/25/2016)... Mexico (PRWEB) , ... May 25, 2016 , ... Casa ... the restorative properties of precious stones to complement its new wellness suites . ... two floors and feature a plethora of special services and insuite amenities, from a ...
(Date:5/25/2016)... ... ... more than fifty years, we've suffered whiplash as each new scientific study seemed to contradict ... nutritional advice – advice that was supposed to keep us healthy and slim. And what ... are considered to be overweight and more than 1 in 3 adults are considered to ...
(Date:5/25/2016)... ... 25, 2016 , ... Researchers from SUNY State College of Optometry won the ... visual evoked potential and human attention. The article, VEP and Human Attention: Translation ... ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) to record ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
(Date:5/24/2016)... 2016 ARANZ Medical  Ltd a ... sector, has been named the Coretex Hi-Tech Emerging Company of ... Dr Bruce Davey , CEO of ARANZ Medical ... really good to be recognised for the work we are ... used in 35 countries around the world from Sub-Saharan Africa ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology: